gms | German Medical Science

29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga

Deutsche Hochdruckliga e. V. DHL ® - Deutsche Hypertonie Gesellschaft Deutsches Kompetenzzentrum Bluthochdruck

23. bis 25.11.2005, Berlin

Olmebest Study: Reduction of blood pressure in the treatment of patients with mild to moderate essential hypertension-the onset of efficacy

Olmebest Studie: Blutdrucksenkung in der Behandlung von Patienten mit leichter bis mittelschwerer essentieller Hypertonie: Eintritt der Wirksamkeit

Meeting Abstract

Suche in Medline nach

  • S. Ewald - Sankyo Pharma GmbH München (München, D)

Hypertonie 2005. 29. Wissenschaftlicher Kongress der Deutschen Hochdruckliga. Berlin, 23.-25.11.2005. Düsseldorf, Köln: German Medical Science; 2006. Doc05hochP30

Die elektronische Version dieses Artikels ist vollständig und ist verfügbar unter: http://www.egms.de/de/meetings/hoch2005/05hoch030.shtml

Veröffentlicht: 8. August 2006

© 2006 Ewald.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielf&aauml;ltigt, verbreitet und &oauml;ffentlich zug&aauml;nglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

OBJECTIVE: Newer data from hypertension outcome trials highlight the necessity of a quick and effective reduction of blood pressure; Olmesartan has demonstrated that a profound reduction of blood pressure can be expected within the first 14 treatment days which should be verified by this study.

DESIGN: The OLMEBEST study, a multinational, multicentre, partly randomised, double blind study in-vestigated the efficacy of a stepped care approach to treatment with Olmesartan 20 mg in the first step. After 14 days Placebo run-in patients received open label 20 mg Olmesartan for 8 weeks. Normalisers were de-fined as patients whose DBP was <90 mmHg after 8 weeks.

RESULTS: A total of 1463 patients (758 male/705 female; Ø 55.7 years; Ø BMI 29 kg/m2) in 346 study sites entered the study. After 8 weeks treatment with Olmesartan, mean sitting BP decreased from 156.3/97.8 mm Hg to 140.4/86.5 mm Hg in the total population. Mean reduction from baseline after 8 weeks treatment in sitting DBP was 11.5 mm Hg (normalisers: 14.3 mm Hg) and SBP was 17.4 mm Hg (normalisers: 19.9 mmHg). The majority of blood pressure reduction was achieved within the first 14 days (SBP/DBP total population 70.2%/68%; normalisers 66.8%/63.2%).

CONCLUSIONS: Olmesartan once daily confirmed the early onset of the antihypertensive efficacy of Olmesartan, with the majority of the BP-lowering effect having occurred within the first 2 weeks of treatment.

Figure 1 [Fig. 1]